Laura Beretta

Peer-Reviewed Articles

1. Twam A, Smith SA, Eltaher M, Boriek Z, Celaya A, Bourgeois D, Martinus D, Calderone TL, Beretta L, Sanchez JI, Victor DW, Gupta N, Hasan M, Prasun JK, Koay EJ, Fuentes DT. Developing a Fully Automated Imaging Biomarker for HCC Risk Assessment via MRI-Based Tumor Segmentation and EPM. Scientific Reports, 2026. e-Pub 2026.
2. Kwan SY, Dolapchiev LI, Sanchez CI, Calderone TL, Sanchez JI, Bhongade MB, El Sabagh A, Cleere DW, Gupta N, Jalal PK, Victor DW, Beretta L. Blood bacterial DNA signatures in a prospective cohort of patients with MASLD cirrhosis. Hepatology Communications 9(7), 2025. e-Pub 2025. PMID: 40489758.
3. Woodland M, Patel H, Castelo A, MA Taie, Eltaher M, Yung JP, Tucker NJ, Calderone TL, Sanchez JI, Cleere DW, Elsaiey A, Gupta N, Victor DW, Beretta L, Patel AB, Brock KK. Dimensionality Reduction and Nearest Neighbors for Improving Out-of-Distribution Detection in Medical Image Segmentation. J Mach Learn Biomed Imaging (MELBA) 2(UNSURE2023 special issue):2006-2052, 2024. e-Pub 2024. PMID: 40453064.
4. Dolapchiev LI, Gonzales KA, Cruz LR, Gagea M, Stevenson HL, Kwan SY, Beretta L. Gut Microbiome and Hepatic Transcriptomic Determinants of HCC Development in Mice with Metabolic Dysfunction-Associated Steatohepatitis. Journal of Hepatocellular Carcinoma 11:1891-1905, 2024. e-Pub 2024. PMID: 39372712.
5. Kwan S-Y, Sabotta CM, Cruz LR, Wong MC, Ajami NJ, McCormick JB, Fisher-Hoch SP, Beretta L. Gut phageome in Mexican Americans: a population at high risk for metabolic dysfunction-associated steatotic liver disease and Diabetes. mSystems 9(9):e0043424, 2024. e-Pub 2024. PMID: 39166873.
6. Patel N, Celaya A, Eltaher M, Glenn R, Savannah KB, Brock KK, Sanchez JI, Calderone TL, Cleere D, Elsaiey A, Cagley M, Gupta N, Victor D, Beretta L, Koay EJ, Netherton TJ, Fuentes DT. Training robust T1-weighted magnetic resonance imaging liver segmentation models using ensembles of datasets with different contrast protocols and liver disease etiologies. Scientific reports 14(1):20988, 2024. e-Pub 2024. PMID: 39251664.
7. Sanchez JI, Fontillas AC, Kwan S-Y, Sanchez CI, Calderone TL, Lee JL, Elsaiey A, Cleere DW, Wei P, Vierling JM, Victor DW, Beretta L. Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis. JHEP Reports 6(8):101119, 2024. e-Pub 2024. PMID: 39139459.
8. Patel N, Eltaher M, Glenn R, Savannah KB, Brock K, Sanchez J, Calderone T, Cleere D, Elsaiey A, Cagley M, Gupta N, Victor D, Beretta L, Celaya A, Koay E, Netherton T, Fuentes D. Training Robust T1-Weighted Magnetic Resonance Imaging Liver Segmentation Models Using Ensembles of Datasets with Different Contrast Protocols and Liver Disease Etiologies. Res Sq, 2024. e-Pub 2024. PMID: 38746406.
9. Nikzad, N, Fuentes, DA, Roach, MA, Chowdhury, T, Cagley, MC, Badawy, M, Elkhesen, A, Hassan, MM, Elsayes, KM, Beretta, L, Koay, EJ, Jalal, P. Enhancement Pattern Mapping for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. Journal of Hepatocellular Carcinoma 11:595-606, 2024. e-Pub 2024. PMID: 38525156.
10. Kwan S-Y, Gonzales KA, Jamal MA, Stevenson HL, Tan L, Lorenzi PL, Futreal PA, Hawk ET, McCormick JB, Fisher-Hoch SP, Jenq RR, Beretta L. Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism. Gut Microbes 16(1):2399260, 2024. e-Pub 2024. PMID: 39239875.
11. Saldarriaga, OA, Wanninger, T, Arroyave, E, Gosnell, J, Krishnan, S, Oneka, MD, Bao, D, Millian, DE, Kueht, ML, Moghe, A, Jiao, J, Sanchez, JI, Spratt, HM, Beretta, L, Uppore Kukkillaya, AR, Burks, JK, Stevenson, HL. Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis. JHEP Reports 6(1), 2023. e-Pub 2023. PMID: 38162144.
12. Zhang, Y, Zhao, Z, Huang, L, Liu, Y, Yao, J, Sun, C, Li, Y, Zhang, Z, Ye, Y, Yuan, F, Nguyen, TK, Garlapati, NR, Wu, A, Egranov, SD, Caudle, AS, Sahin, AA, Lim, B, Beretta, L, Calin, GA, Yu, D, Hung, MC, Curran, M, Rezvani, K, Gan, B, Tan, Z, Han, L, Lin, C, Yang, L. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metabolism 35(8):1457-1473.e13, 2023. e-Pub 2023. PMID: 37329887.
13. Engel, BJ, Paolillo, V, Uddin, M, Gonzales, KA, McGinnis, K, Sutton, M, Patnana, M, Grindel, B, Gores, GJ, Piwnica-Worms, D, Beretta, L, Pisaneschi, F, Gammon, ST, Millward, S. Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging. Cancers 15(15), 2023. e-Pub 2023. PMID: 37568603.
14. Sanchez, JI, Parra Cuentas, ER, Jiao, J, Solis Soto, LM, Ledesma, D, Saldarriaga, OA, Stevenson, HL, Beretta, L. Cellular and Molecular Mechanisms of Liver Fibrosis in Patients with NAFLD. Cancers 15(11), 2023. e-Pub 2023. PMID: 37296834.
15. Saldarriaga OA, Krishnan S, Wanninger TG, Oneka M, Rao A, Bao D, Arroyave E, Gosnell J, Kueht M, Moghe A, Millian D, Jiao J, Sanchez JI, Spratt H, Beretta L, Stevenson HL. Patients with fibrosis from non-alcoholic steatohepatitis have heterogeneous intrahepatic macrophages and therapeutic targets. medRxiv, 2023. e-Pub 2023. PMID: 36865099.
16. Jiao J, Sanchez JI, Saldarriaga OA, Solis LM, Tweardy DJ, Maru DM, Stevenson HL, Beretta L. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease. JHEP Rep 5(2):100628, 2023. e-Pub 2023. PMID: 36687470.
17. Kwan SY, Slayden AN, Coronado AR, Marquez RC, Chen H, Wei P, Savage MI, Vornik LA, Fox JT, Sei S, Liang D, Stevenson HL, Wilkerson GK, Gagea M, Brown PH, Beretta L. Treatment Strategies and Mechanisms Associated with the Prevention of NASH-Associated HCC by a Toll-like Receptor 4 Inhibitor. Cancer Prev Res (Phila) 16(1):17-28, 2023. e-Pub 2023. PMID: 36162136.
18. Sabotta CM, Kwan SY, Petty LE, Below JE, Joon A, Wei P, Fisher-Hoch SP, McCormick JB, Beretta L. Genetic variants associated with circulating liver injury markers in Mexican Americans, a population at risk for non-alcoholic fatty liver disease. Front Genet 13:995488, 2022. e-Pub 2022. PMID: 36386790.
19. Kwan SY, Sabotta CM, Joon A, Wei P, Petty LE, Below JE, Wu X, Zhang J, Jenq RR, Hawk ET, McCormick JB, Fisher-Hoch SP, Beretta L. Gut Microbiome Alterations Associated with Diabetes in Mexican Americans in South Texas. mSystems 7(3):e0003322, 2022. e-Pub 2022. PMID: 35477306.
20. Kwan SY, Jiao J, Joon A, Wei P, Petty LE, Below JE, Daniel CR, Wu X, Zhang J, Jenq RR, Futreal PA, Hawk ET, McCormick JB, Fisher-Hoch SP, Beretta L. Gut Microbiome Features Associated with Liver Fibrosis in Hispanics, a Population at High Risk for Fatty Liver Disease. Hepatology 75(4):955-967, 2022. e-Pub 2022. PMID: 34633706.
21. Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 7(3):208-218, 2022. e-Pub 2022. PMID: 35065057.
22. Sanchez JI, Jiao J, Kwan SY, Veillon L, Warmoes MO, Tan L, Odewole M, Rich NE, Wei P, Lorenzi PL, Singal AG, Beretta L. Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila) 14(10):955-962, 2021. e-Pub 2021. PMID: 34253566.
23. Jiao J, Kwan SY, Sabotta CM, Tanaka H, Veillon L, Warmoes MO, Lorenzi PL, Wang Y, Wei P, Hawk ET, Almeda JL, McCormick JB, Fisher-Hoch SP, Beretta L. Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev 30(9):1643-1651, 2021. e-Pub 2021. PMID: 34155064.
24. Jiao J, Sanchez JI, Thompson EJ, Mao X, McCormick JB, Fisher-Hoch SP, Futreal PA, Zhang J, Beretta L. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics. Int J Mol Sci 22(14), 2021. e-Pub 2021. PMID: 34299031.
25. Khan IM, Gjuka D, Jiao J, Song X, Wang Y, Wang J, Wei P, El-Serag HB, Marrero JA, Beretta L. A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila) 14(6):667-674, 2021. e-Pub 2021. PMID: 33685927.
26. Qayyum A, Bhosale P, Aslam R, Avritscher R, Ma J, Pagel MD, Sun J, Mohamed Y, Rashid A, Beretta L, Kaseb AO. Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. Abdom Radiol (NY) 46(3):1008-1015, 2021. e-Pub 2021. PMID: 32974761.
27. Watt GP, De La Cerda I, Pan JJ, Fallon MB, Beretta L, Loomba R, Lee M, McCormick JB, Fisher-Hoch SP. Elevated Glycated Hemoglobin Is Associated With Liver Fibrosis, as Assessed by Elastography, in a Population-Based Study of Mexican Americans. Hepatol Commun 4(12):1793-1801, 2020. e-Pub 2020. PMID: 33305150.
28. Saldarriaga OA, Freiberg B, Krishnan S, Rao A, Burks J, Booth AL, Dye B, Utay N, Ferguson M, Akil A, Yi M, Beretta L, Stevenson HL. Multispectral Imaging Enables Characterization of Intrahepatic Macrophages in Patients With Chronic Liver Disease. Hepatol Commun 4(5):708-723, 2020. e-Pub 2020. PMID: 32363321.
29. Kwan SY, Jiao J, Qi J, Wang Y, Wei P, McCormick JB, Fisher-Hoch SP, Beretta L. Bile Acid Changes Associated With Liver Fibrosis and Steatosis in the Mexican-American Population of South Texas. Hepatol Commun 4(4):555-568, 2020. e-Pub 2020. PMID: 32258950.
30. Watt GP, Lee M, Pan JJ, Fallon MB, Loomba R, Beretta L, McCormick JB, Fisher-Hoch SP. High prevalence of hepatic fibrosis, measured by Elastography, in a Population-based study of Mexican Americans. Clin Gastroenterol Hepatol S1542-3565((18)):30599-8, 2019. e-Pub 2019. PMID: 29902644.
31. Feng Z, Marrero JA, Khaderi S, Singal AG, Kanwal F, Loo N, Beretta L, Ning J, El-Serag HB. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol 114(3):530-532, 2019. e-Pub 2019. PMID: 30699099.
32. Vriens K, Christen S, Parik S, Broekaert D, Yoshinaga K, Talebi A, Dehairs J, Escalona-Noguero C, Schmieder R, Cornfield T, Charlton C, Romero-Pérez L, Rossi M, Rinaldi G, Orth MF, Boon R, Kerstens A, Kwan SY, Faubert B, Méndez-Lucas A, Kopitz CC, Chen T, Fernandez-Garcia J, Duarte JAG, Schmitz A, Steigemann P, Najimi M, Hägebarth A, Van Ginderachter JO, Sokal E, Gotoh N, Wong KK, Verfaillie C, Derua R, Munck S, Yuneva M, Beretta L, DeBerardinis RJ, Swinnen JV, Hodson L, Cassiman D, Verslype C, Christian S, Grünewald S, Grünewald TGP, S-M F. Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature 566(7744):403-406, 2019. e-Pub 2019. PMID: 30728499.
33. Nguyen J, Jiao J, Smoot K, Watt GP, Zhao C, Song X, Stevenson HL, McCormick JB, Fisher-Hoch SP, Zhang J, Futreal PA, Beretta L. Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis. Oncotarget 29(9(50)):29495-29507, 2018. e-Pub 2018. PMID: 30034633.
34. Jiao J, Watt GP, Stevenson HL, Calderone TC, Fisher-Hoch SP, Ye Y, Wu X, Vierling JM, Beretta L. Telomerase Reverse Transcriptase Mutations in Plasma DNA in Patients with HCC or Cirrhosis: Prevalence and Risk factors. Hepatol Commun 27(2(6)):718-731, 2018. e-Pub 2018. PMID: 29881823.
35. Jiao J, Niu W, Wang Y, Baggerly KA, Ye Y, Wu X, Davenport D, Almeda JL, Betancourt-Garcia MM, Forse RA, Stevenson HL, Watt GP, McCormick JB, Fisher-Hoch SP, Beretta L. Prevalence of Aflatoxin-associated TP53 R249S mutation in Hepatocellular Carcinoma in Hispanics in South Texas. Cancer Prev Res (Phila) 11(2)(103-112), 2018. e-Pub 2018. PMID: 29089331.
36. Jiao J, Gonzalez A, Stevenson HL, Gagea M, Sugimoto H, Kalluri R, Beretta L. Depletion of S100A4+ stromal cells doesn't prevent HCC development but reduces the stem-like phenotype of the tumors. Exp Mol Med 5(50(1)):e422, 2018. e-Pub 2018. PMID: 29303514.
37. Jung KH, Yoo W, Stevenson HL, Deshpande D, Shen H, Gagea M, Yoo SY, Wang J, Eckols TK, Bharadwaj U, Tweardy DJ, Beretta L. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice. Clin Cancer Res 23(18):5537-5546, 2017. e-Pub 2017. PMID: 28533225.
38. Yoo W, Gjuka D, Stevenson HL, Song X, Shen H, Yoo SY, Wang J, Fallon M, Ioannou GN, Harrison SA, Beretta L. Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. PLoS One 12(12):e0189965, 2017. e-Pub 2017. PMID: 29244873.
39. Ratti F, Cipriani F, Reineke R, Catena M, Comotti L, Beretta L, Aldrighetti L. Impact of ERAS approach and minimally-invasive techniques on outcome of patients undergoing liver surgery for hepatocellular carcinoma. Dig Liver Dis 48(10):1243-8, 2016. e-Pub 2016. PMID: 27522551.
40. Duarte-Salles T, Misra S, Stepien M, Plymoth A, Muller DC, Overvad K, Olsen A, Tjonneland A, Baglietto L, Severi G, Boutron-Ruault MC, Turzanski-Fortner R, Kaaks R, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Bamia C, Pala V, Palli D, Mattiello A, Tumino R, Naccarati A, Bueno-de-Mesquita HB, Peeters PH, Weiderpass E, Quiros JR, Agudo A, Sanchez-Cantalejo E, Ardanaz E, Gavrila D, Dorronsoro M, Werner M, Hemmingsson O, Ohlsson B, Sjöberg K, Wareham NJ, Khaw KT, Bradbury KE, Gunter MJ, Cross AJ, Riboli E, Jenab M, Hainaut P, Beretta L. Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. Cancer Prev Res (Phila) 9(9):758-65, 2016. e-Pub 2016. PMID: 27339170.
41. Watt GP, Vatcheva KP, Griffith DM, Reininger BM, Beretta L, Fallon MB, McCormick JB, Fisher-Hoch SP. The Precarious Health of Young Mexican American Men in South Texas, Cameron County Hispanic Cohort, 2004-2015. Prev Chronic Dis 13:E113, 2016. e-Pub 2016. PMID: 27560721.
42. Jung KH, McCarthy RL, Zhou C, Uprety N, Barton MC, Beretta L. MicroRNA Regulates Hepatocytic Differentiation of Progenitor Cells by Targeting YAP1. Stem Cells 34(5):1284-96, 2016. e-Pub 2016. PMID: 26731713.
43. Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Beretta L. Differentiation Therapy for Hepatocellular Carcinoma: multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology 63(3):864-79, 2016. e-Pub 2016. PMID: 26599259.
44. Watt GP, Vatcheva KP, Beretta L, Pan JJ, Fallon MB, McCormick JB, Fisher-Hoch SP. Hepatitis C virus in Mexican Americans: a population-based study reveals relatively high prevalence and negative association with diabetes. Epidemiol Infect 144(2):297-305, 2016. e-Pub 2016. PMID: 26088260.
45. Jiao J, Watt GP, Lee M, Rahbar MH, Vatcheva KP, Pan JJ, McCormick JB, Fisher-Hoch SP, Fallon MB, Beretta L. Cirrhosis and Advanced Fibrosis in Hispanics in Texas: the Dominant Contribution of Central Obesity. PLoS One 11(3):e0150978, 2016. e-Pub 2016. PMID: 26950933.
46. Zou RH, Lin QG, Huang W, Li XL, Cao Y, Zhang J, Zhou JH, Li AH, Beretta L, Qian CN. Quantitative Contrast-Enhanced Ultrasonic Imaging Reflects Microvascularization in Hepatocellular Carcinoma and Prognosis after Resection. Ultrasound Med Biol 41(10):2621-30, 2015. e-Pub 2015. PMID: 26210785.
47. Pan JJ, Fisher-Hoch SP, Chen C, Feldstein AE, McCormick JB, Rahbar MH, Beretta L, Fallon MB. Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort. World J Hepatol 7(11):1586-94, 2015. e-Pub 2015. PMID: 26085918.
48. Zhang J, Jiao J, Cermelli S, Muir K, Jung KH, Zou R, Rashid A, Gagea M, Zabludoff S, Kalluri R, Beretta L. MiR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. Cancer Res 75(9):1859-67, 2015. e-Pub 2015. PMID: 25769721.
49. da Costa AN, Plymoth A, Santos-Silva D, Ortiz-Cuaran S, Camey S, Guilloreau P, Sangrajrang S, Khuhaprema T, Mendy M, Lesi OA, Chang HK, Oh JK, Lee DH, Shin HR, Kirk GD, Merle P, Beretta L, Hainaut P. Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. Int J Cancer 136(1):172-81, 2015. e-Pub 2015. PMID: 24803312.
50. Muir K, Hazim A, He Y, Peyressatre M, Kim DY, Song X, Beretta L. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res 73(15):4722-31, 2013. e-Pub 2013. PMID: 23749645.
51. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, Hainaut P, Marrero JA, Beretta L. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 55(2):483-90, 2012. e-Pub 2012. PMID: 21953299.
52. Elortza F, Beretta L, Zhang X, He F, Mato JM. The 2011 Human Liver Proteome Project (HLPP) Workshop September 5, 2011, Geneva, Switzerland. Proteomics 12(1):5-8, 2012. e-Pub 2012. PMID: 22106089.
53. Legrain P, Aebersold R, Archakov A, Bairoch A, Bala K, Beretta L, Bergeron J, Borchers CH, Corthals GL, Costello CE, Deutsch EW, Domon B, Hancock W, He F, Hochstrasser D, Marko-Varga G, Salekdeh GH, Sechi S, Snyder M, Srivastava S, Uhlén M, Wu CH, Yamamoto T, Paik YK, Omenn GS. The human proteome project: current state and future direction. Mol Cell Proteomics 10(7):M111.009993, 2011. e-Pub 2011. PMID: 21742803.
54. Lai KK, Shang S, Lohia N, Booth GC, Masse DJ, Fausto N, Campbell JS, Beretta L. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models. PLoS Genet 7(6):e1002147, 2011. e-Pub 2011. PMID: 21731504.
55. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6(8):e23937, 2011. e-Pub 2011. PMID: 21886843.
56. Gao X, Zheng J, Beretta L, Mato J, He F. The 2009 Human Liver Proteome Project (HLPP) Workshop 26 September 2009, Toronto, Canada. Proteomics 10(17):3058-61, 2010. e-Pub 2010. PMID: 20806223.
57. Beretta L. Liver proteomics applied to translational research in liver disease and cancer. Proteomics Clin Appl 4(4):359-61, 2010. e-Pub 2010. PMID: 21137055.
58. Beretta L. HUPO's effort to define the liver proteome. J Proteome Res 9(2):637-8, 2010. e-Pub 2010. PMID: 20092292.
59. Olson KE, Booth GC, Poulin F, Sonenberg N, Beretta L. Impaired myelopoiesis in mice lacking the repressors of translation initiation, 4E-BP1 and 4E-BP2. Immunology 128(1 Suppl):e376-84, 2009. e-Pub 2009. PMID: 19175792.
60. Parent R, Qu X, Petit MA, Beretta L. The heat shock cognate protein 70 is associated with hepatitis C virus particles and modulates virus infectivity. Hepatology 49(6):1798-809, 2009. e-Pub 2009. PMID: 19434724.
61. Lee NP, Chen L, Lin MC, Tsang FH, Yeung C, Poon RT, Peng J, Leng X, Beretta L, Sun S, Day PJ, Luk JM. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J Proteome Res 8(3):1293-303, 2009. e-Pub 2009. PMID: 19161326.
62. Beretta L. The Human Liver Proteome Project (HLPP) Workshop, August 2008, Amsterdam, The Netherlands. Proteomics 9(21):4830-4833, 2009. e-Pub 2009. PMID: 19862759.
63. Zheng J, Gao X, Mato J, Beretta L, He F. Report of the 9th HLPP Workshop October 2007, Seoul, Korea. Proteomics 8(17):3420-3, 2008. e-Pub 2008. PMID: 18683817.
64. Lai KK, Kolippakkam D, Beretta L. Comprehensive and quantitative proteome profiling of the mouse liver and plasma. Hepatology 47(3):1043-51, 2008. e-Pub 2008. PMID: 18266228.
65. Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, Lau GK, Beretta L, Fan ST. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics 7(2):315-25, 2008. e-Pub 2008. PMID: 17934217.
66. Parent R, Beretta L. Translational control plays a prominent role in the hepatocytic differentiation of HepaRG liver progenitor cells. Genome Biol 9(1):R19, 2008. e-Pub 2008. PMID: 18221535.
67. Beretta L. The Human Liver Proteome Project. Mol Cell Proteomics 6(11):2043, 2007. e-Pub 2007.
68. Beretta L. Proteomics from the clinical perspective: many hopes and much debate. Nat Methods 4(10):785-6, 2007. e-Pub 2007. PMID: 17901867.
69. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 5(8):938-45, 945.e1-4, 2007. e-Pub 2007. PMID: 17509946.
70. Bergeron J, Beretta L. Barbados Conference 2007. Mol Cell Proteomics 6(7):1287-1288, 2007. e-Pub 2007.
71. Parent R, Kolippakkam D, Booth G, Beretta L. Mammalian target of rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth. Cancer Res 67(9):4337-45, 2007. e-Pub 2007. PMID: 17483347.
72. Mato JM, He F, Beretta L. The 2006 Human Liver Proteome Project (HLPP) Workshops. Proteomics Clin Appl 1(5):442-5, 2007. e-Pub 2007. PMID: 21136695.
73. Mannová P, Fang R, Wang H, Deng B, McIntosh MW, Hanash SM, Beretta L. Modification of host lipid raft proteome upon hepatitis C virus replication. Mol Cell Proteomics 5(12):2319-25, 2006. e-Pub 2006. PMID: 16943187.
74. Chignard N, Shang S, Wang H, Marrero J, Bréchot C, Hanash S, Beretta L. Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: Detection of generated fragments in patient sera. Gastroenterology 130(7):2010-22, 2006. e-Pub 2006. PMID: 16762624.
75. Zheng J, Gao X, Beretta L, He F. The Human Liver Proteome Project (HLPP) workshop during the 4th HUPO World Congress. Proteomics 6(6):1716-8, 2006. e-Pub 2006. PMID: 16525995.
76. Mannová P, Beretta L. Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J Virol 79(14):8742-9, 2005. e-Pub 2005. PMID: 15994768.
77. Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem 279(43):45194-207, 2004. e-Pub 2004. PMID: 15308637.
78. Girard S, Vossman E, Misek DE, Podevin P, Hanash S, Bréchot C, Beretta L. Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses. Hepatology 40(3):708-18, 2004. e-Pub 2004. PMID: 15349911.
79. Kasinathan C, Vrana K, Beretta L, Thomas P, Gooch R, Worst T, Walker S, Xu A, Pierre P, Green H, Grant K, Manowitz P. The future of proteomics in the study of alcoholism. Alcohol Clin Exp Res 28(2):228-32, 2004. e-Pub 2004. PMID: 15112930.
80. Rolli-Derkinderen M, Machavoine F, Baraban JM, Grolleau A, Beretta L, Dy M. ERK and p38 inhibit the expression of 4E-BP1 repressor of translation through induction of Egr-1. J Biol Chem 278(21):18859-67, 2003. e-Pub 2003. PMID: 12618431.
81. Grolleau A, Bowman J, Pradet-Balade B, Puravs E, Hanash S, Garcia-Sanz JA, Beretta L. Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J Biol Chem 277(25):22175-84, 2002. e-Pub 2002. PMID: 11943782.
82. Singer NG, Fox DA, Haqqi TM, Beretta L, Endres JS, Prohaska S, Parnes JR, Bromberg J, Sramkoski RM. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. Int Immunol 14(6):585-97, 2002. e-Pub 2002. PMID: 12039910.
83. Girard S, Shalhoub P, Lescure P, Sabile A, Misek DE, Hanash S, Bréchot C, Beretta L. An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology 295(2):272-83, 2002. e-Pub 2002. PMID: 12033786.
84. Le Naour F, Brichory F, Misek DE, Bréchot C, Hanash SM, Beretta L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 1(3):197-203, 2002. e-Pub 2002. PMID: 12096119.
85. Hanash SM, Beretta LM. Operomics: integrated genomic and proteomic profiling of cells and tissues. Brief Funct Genomic Proteomic 1(1):10-22, 2002. e-Pub 2002. PMID: 15251063.
86. Delhem N, Sabile A, Gajardo R, Podevin P, Abadie A, Blaton MA, Kremsdorf D, Beretta L, Brechot C. Activation of the interferon-inducible protein kinase PKR by hepatocellular carcinoma derived-hepatitis C virus core protein. Oncogene 20(41):5836-45, 2001. e-Pub 2001. PMID: 11593389.
87. Podevin P, Sabile A, Gajardo R, Delhem N, Abadie A, Lozach PY, Beretta L, Bréchot C. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner. Hepatology 33(6):1503-11, 2001. e-Pub 2001. PMID: 11391540.
88. Le Naour F, Hohenkirk L, Grolleau A, Misek DE, Lescure P, Geiger JD, Hanash S, Beretta L. Profiling changes in gene expression during differentiation and maturation of monocyte-derived dendritic cells using both oligonucleotide microarrays and proteomics. J Biol Chem 276(21):17920-31, 2001. e-Pub 2001. PMID: 11279020.
89. Grolleau A, Kaplan MJ, Hanash SM, Beretta L, Richardson B. Impaired translational response and increased protein kinase PKR expression in T cells from lupus patients. J Clin Invest 106(12):1561-8, 2000. e-Pub 2000. PMID: 11120763.
90. Baron-Delage S, Abadie A, Echaniz-Laguna A, Melki J, Beretta L. Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. Mol Med 6(11):957-68, 2000. e-Pub 2000. PMID: 11147573.
91. Grolleau A, Wietzerbin J, Beretta L. Defect in the regulation of 4E-BP1 and 2, two repressors of translation initiation, in the retinoid acid resistant cell lines, NB4-R1 and NB4-R2. Leukemia 14(11):1909-14, 2000. e-Pub 2000. PMID: 11069026.
92. Kaplan MJ, Beretta L, Yung RL, Richardson BC. LFA-1 overexpression and T cell autoreactivity: mechanisms. Immunol Invest 29(4):427-42, 2000. e-Pub 2000. PMID: 11130784.
93. Grolleau A, Sonenberg N, Wietzerbin J, Beretta L. Differential regulation of 4E-BP1 and 4E-BP2, two repressors of translation initiation, during human myeloid cell differentiation. J Immunol 162(6):3491-7, 1999. e-Pub 1999. PMID: 10092805.
94. Beretta L, Singer NG, Hinderer R, Gingras AC, Richardson B, Hanash SM, Sonenberg N. Differential regulation of translation and eIF4E phosphorylation during human thymocyte maturation. J Immunol 160(7):3269-73, 1998. e-Pub 1998. PMID: 9531283.
95. Beretta L, Grolleau A. Rapamycin selectively inhibits a growth-dependent activation of the initiation step of translation. Médecine/Sciences 14:600-602, 1998. e-Pub 1998.
96. Beretta L, Svitkin YV, Sonenberg N. Rapamycin stimulates viral protein synthesis and augments the shutoff of host protein synthesis upon picornavirus infection. J Virol 70(12):8993-6, 1996. e-Pub 1996. PMID: 8971030.
97. Beretta L, Gabbay M, Berger R, Hanash SM, Sonenberg N. Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5q- associated leukemias. Oncogene 12(7):1593-6, 1996. e-Pub 1996. PMID: 8622878.
98. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 15(3):658-64, 1996. e-Pub 1996. PMID: 8599949.
99. Beretta L, Dubois MF, Sobel A, Bensaude O. Stathmin is a major substrate for mitogen-activated protein kinase during heat shock and chemical stress in HeLa cells. Eur J Biochem 227(1-2):388-95, 1995. e-Pub 1995. PMID: 7851413.
100. Beretta L, Dobránsky T, Sobel A. Multiple phosphorylation of stathmin. Identification of four sites phosphorylated in intact cells and in vitro by cyclic AMP-dependent protein kinase and p34cdc2. J Biol Chem 268(27):20076-84, 1993. e-Pub 1993. PMID: 8376365.
101. Hanash SM, Beretta L, Barcroft CL, Sheldon S, Glover TW, Ungar D, Sonenberg N. Mapping of the gene for interferon-inducible dsRNA-dependent protein kinase to chromosome region 2p21-22: a site of rearrangements in myeloproliferative disorders. Genes Chromosomes Cancer 8(1):34-7, 1993. e-Pub 1993. PMID: 7691157.
102. Doye V, Le Gouvello S, Dobransky T, Chneiweiss H, Beretta L, Sobel A. Expression of transfected stathmin cDNA reveals novel phosphorylated forms associated with developmental and functional cell regulation. Biochem J 287 ( Pt 2):549-54, 1992. e-Pub 1992. PMID: 1445213.
103. Beretta L, Boutterin MC, Drouva SV, Sobel A. Phosphorylation of a group of proteins related to the physiological, multihormonal regulations of the various cell types in the anterior pituitary gland. Endocrinology 125(3):1358-64, 1989. e-Pub 1989. PMID: 2788076.
104. Chneiweiss H, Beretta L, Cordier J, Boutterin MC, Glowinski J, Sobel A. Stathmin is a major phosphoprotein and cyclic AMP-dependent protein kinase substrate in mouse brain neurons but not in astrocytes in culture: regulation during ontogenesis. J Neurochem 53(3):856-63, 1989. e-Pub 1989. PMID: 2474633.
105. Doye V, Soubrier F, Bauw G, Boutterin MC, Beretta L, Koppel J, Vandekerckhove J, Sobel A. A single cDNA encodes two isoforms of stathmin, a developmentally regulated neuron-enriched phosphoprotein. J Biol Chem 264(21):12134-7, 1989. e-Pub 1989. PMID: 2745432.
106. Beretta L, Houdouin F, Sobel A. Identification of two distinct isoforms of stathmin and characterization of their respective phosphorylated forms. J Biol Chem 264(17):9932-8, 1989. e-Pub 1989. PMID: 2722886.
107. Sobel A, Boutterin MC, Beretta L, Chneiweiss H, Doye V, Peyro-Saint-Paul H. Intracellular substrates for extracellular signaling. Characterization of a ubiquitous, neuron-enriched phosphoprotein (stathmin). J Biol Chem 264(7):3765-72, 1989. e-Pub 1989. PMID: 2917975.
108. Beretta L, Boutterin MC, Sobel A. Phosphorylation of intracellular proteins related to the multihormonal regulation of prolactin: comparison of normal anterior pituitary cells in culture with the tumor-derived GH cell lines. Endocrinology 122(1):40-51, 1988. e-Pub 1988. PMID: 3121285.
109. Beretta L, Sobel A. [Phosphorylation of cytoplasmic proteins related to the multihormonal regulation of anterior pituitary cells]. Ann Endocrinol (Paris) 47(1):57-8, 1986. e-Pub 1986. PMID: 3094426.

Review Articles

1. Beretta L. Comparative analysis of the liver and plasma proteomes as a novel and powerful strategy for hepatocellular carcinoma biomarker discovery. Cancer Lett 286(1):134-9, 2009. e-Pub 2009. PMID: 19232462.
2. Feng JT, Shang S, Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene 25(27):3810-7, 2006. e-Pub 2006. PMID: 16799622.
3. Parent R, Beretta L. Proteomics in the study of liver pathology. J Hepatol 43(1):177-83, 2005. e-Pub 2005. PMID: 15894398.
4. Chignard N, Beretta L. Proteomics for hepatocellular carcinoma marker discovery. Gastroenterology 127(5 Suppl 1):S120-5, 2004. e-Pub 2004. PMID: 15508075.
5. Beretta L. Translational control in T lymphocytes. Int Rev Immunol 23(3-4):347-63, 2004. e-Pub 2004. PMID: 15204093.
6. Richards J, Le Naour F, Hanash S, Beretta L. Integrated genomic and proteomic analysis of signaling pathways in dendritic cell differentiation and maturation. Ann N Y Acad Sci 975:91-100, 2002. e-Pub 2002. PMID: 12538157.
7. Naour FL, Brichory F, Beretta L, Hanash SM. Identification of tumor-associated antigens using proteomics. Technol Cancer Res Treat 1(4):257-62, 2002. e-Pub 2002. PMID: 12625784.
8. Dua K, Williams TM, Beretta L. Translational control of the proteome: relevance to cancer. Proteomics 1(10):1191-9, 2001. e-Pub 2001. PMID: 11721631.
9. Shalhoub P, Kern S, Girard S, Beretta L. Proteomic-based approach for the identification of tumor markers associated with hepatocellular carcinoma. Dis Markers 17(4):217-23, 2001. e-Pub 2001. PMID: 11790889.

Other Articles

1. Kwan, SY, Sabotta, CM, Cruz, LR, Wong, M, Ajami, NJ, McCormick, JB, Fisher-Hoch, SP, Beretta, L Erratum. mSystems 9(11):e0129724, 2024. PMID: 39422494.
2. Hassan MM, Li D, Han Y, Byun J, Hatia RI, Long E, Choi J, Kelley RK, Cleary SP, Lok AS, Bracci P, Permuth JB, Bucur R, Yuan JM, Singal AG, Jalal PK, Ghobrial RM, Santella RM, Kono Y, Shah DP, Nguyen MH, Liu G, Parikh ND, Kim R, Wu HC, El-Serag H, Chang P, Li Y, Chun YS, Lee SS, Gu J, Hawk E, Sun R, Huff C, Rashid A, Amin HM, Beretta L, Wolff RA, Antwi SO, Patt Y, Hwang LY, Klein AP, Zhang K, Schmidt MA, White DL, Goss JA, Khaderi SA, Marrero JA, Cigarroa FG, Shah PK, Kaseb AO, Roberts LR, Amos CI Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology 80(1):87-101, 2024. PMID: 38381705.

Abstracts

1. Lucia O, Musat M, Estrada S, Kwan S-Y, Beretta L. Genetic Variants Linked to MASLD and HCC Development in a High-Risk Hispanic Cohort. CPRIT-CURE poster symposium; 7 August 2025; University of Texas MD Anderson Cancer Center, 2025.
2. Becker M, Kwan S-Y, Calderone T, Gupta N, Beretta L. Liver Lesion Stratification in Patients with Cirrhosis: A Predictive Model for Hepatocellular Carcinoma Risk Assessment. Medical Students Summer in Oncology at Anderson Research (SOAR) Program, Final Exposition, The University of Texas at MD Anderson Cancer Center, 2025.
3. Kierski TM, Aji AM, Rojas JD, Gessner RC, Beretta L, Kwan S-Y, Hazle J, Maldonado KL, Kingsley C, Bouchard RR, Czernuszewicz TJ. Automated quantification of small animal liver tumor volume in longitudinal MR imaging using deep learning. Proceedings of the American Association for Cancer Research Annual Meeting 2025 85((8_Suppl_1)):Abstract nr 7444, 2025. e-Pub 2025.
4. Kierski TM, Aji AM, Rojas JD, Gessner RC, Beretta L, Kwan SY, Hazle J, Maldonado KL, Kingsley C, Bouchard RR, Czernuszewicz TJ. Automated quantification of small animal liver tumor volume in longitudinal MR imaging using deep learning. American Association for Cancer Research Annual Meeting 2025 85(8_Suppl_1):1-7509, 2025. e-Pub 2025.
5. Beretta L. The heat shock cognate protein 70 is associated with hepatitis C virus particles and modulates the virus infectivity and release. 13th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD). e-Pub 2009.
6. Dolapchiev LI, Kwan S-Y, Beretta L. Molecular and cellular signatures of hepatocellular carcinoma development in patients with metabolic dysfunction-associated steatotic liver disease. AACR SPECIAL CONFERENCE IN CANCERRESEARCH: MECHANISMS OF CANCER IMMUNITYAND CANCER-RELATED AUTOIMMUNITY.
7. Qi J, Kwan SY, Beretta L. On the Relationship Between the Microbiome and Bile Acids and Their Role In Hepatocellular Carcinoma. 2019 CPRIT Research Training Program at MD Anderson Cancer Center.
8. Smoot K, Kwan S, McDaniel A, Beretta L. Hepatocellular carcinoma prevention: A TLR4-targeted approach. 2019 First Year Medical Student Program at MD Anderson.
9. Beretta L. SPORE in HCC. TRP - Specialized Programs of Research Excellence (SPORE) - NCI.
10. Beretta L. Comparison of intrahepatic macrophage phenotypes in patients with non-alcoholic steatohepatitis (NASH) and different fibrosis stages using multispectral imaging. The Liver Meeting 2019: 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
11. Saldarriaga OA, Jiao J, Beretta L, Freiberg B, Krishnan S, Rao A, Booth A, Stevenson HL. Multispectral Imaging Reveals that Patients with Non-Alcoholic Steatohepatitis (NASH) Harbor Distinctive Intrahepatic Macrophage Phenotypes Depending on Amount of Fibrosis. USCAP 109th Annual Meeting 2020.
12. Saldarriaga OA, Jiao J, Beretta L, Freiberg F, Krishnan K, Rao R, Wanninger T, Stevenson HL. Use of Spectral Imaging and NanoString Platforms to Identify Differences in Pro-fibrotic Microenvironments in Patients with Chronic Liver Disease. USCAP 2021: Liver Pathology.
13. Beretta L. MultiSPECTRAL imaging analysis of liver biopsies from patients with non-alcoholic steatohepatitis and different fibrosis stages reveals enrichment of pathogenic macrophage phenotypes associated with disease progression. International Liver Congress 2022 - European Association for the Study of the Liver (EASL).
14. Beretta L. Multispectral analysis of liver biopsies from patients with chronic hepatitis C reveals unique macrophage phenotypes and spatial interactions associated with fibrosis progression. International Liver Congress 2022 - European Association for the Study of the Liver (EASL).
15. Nikzad N, Fuentes D, Roach M, Chowdhury T, Cagley M, Badawy M, Hassan MM, Elsayes K, Beretta L, Koay EJ, Jalal PK. Characterization of the Imaging Signature of Hepatocellular Carcinoma with Enhancement Pattern Mapping. The Liver Meeting; 2022 (AASLD).
16. Arroyave E, Saldarriaga O, Wanninger T, Millian D, Bhatti S, Jiao J, Sanchez JI, Beretta L, Kueht K, Bao D, Moghe A, Stevenson HL. Comparative Analysis of the Liver Microenvironment in Patients with Autoimmune Hepatitis with Progression or Non-progression to Cirrhosis. USCAP 12th Annual Meeting.
17. Beretta L. Characterization of the imaging signature of hepatocellular carcinoma with enhancement pattern mapping. EASL Congress 2023 (European Association for the Study of the Liver).
18. Nikzad N, Fuentes D, Roach M, Chowdhury T, Cagley M, Badawy M, Hassan MM, Elsayes K, Beretta L, Koay EJ, Jalal PK. Characterization of the Imaging Signature of Hepatocellular Carcinoma with Enhancement Pattern Mapping. EASL Congress 2023.
19. Kwan SY, Jamal MA, Melendez B, Ajami NJ, Jenq RR, Beretta L. Protection Against Fibrosis By A Bacterial Consortium In Metabolic Dysfunction-associated Steatohepatitis And The Role Of Amino Acid Metabolism. 2024 Gut Microbiota for Health World Summit explores the clinical impacts of the microbiome - American Gastroenterological Association (AGA).
20. Nikzad N, Fuentes D, Roach M, Chowdhury T, Cagley M, Badawy M, Hassan MM, Elsayes K, Beretta L, Koay KJ, Jalal P. Characterization of the Imaging Signature of Hepatocellular Carcinoma with Enhancement Pattern Mapping. Digestive Diseases Week 2024 Conference (Co-Sponsored by AASLD).
21. Sanchez, Jessica I., Fontillas, Antoine C., Kwan, Suet-Ying, Sanchez, Caren I., Calderone, Tiffany L., Lee, Jana, Elsaiey, Ahmed, Cleere, Darrel W., Vierling, John M., Victor, David W., Beretta, Laura. Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis [Conference Abstract]. EASL Congress 2024 - The International Liver Congress.
22. Beretta L. Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism. EASL Congress 2024 - The International Liver Congress.
23. Beretta L. Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis. EASL Congress 2024 - The International Liver Congress.
24. Ali J, Li D, Kaseb AO, Beretta L, Rashid A, Hatia RI, Farahat OM, Chun YS, Hassan MM. TM6SF2 Genetic Variation in Relation to Risk and Prognosis of Hepatocellular Carcinoma. 2024 MD Anderson Cancer Center CATALYST (Cancer Advanced Training and Learning for Young Scientists) program and Cancer Prevention Research Training Program.
25. Hatia RI, Wei P, Li D, Chang P, Jalal PK, Chun YS, Rashid A, Beretta L, Kaseb AO, Hassan MM. The associations between circulating metabolic biomarkers on the risk of hepatocellular carcinoma development in the USA. The Liver Meeting 2024: 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
26. Dolapchiev LI, Kwan S-Y, Beretta L. Molecular and Cellular Signatures of Hepatocellular Carcinoma Development in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease. 6th International Conference on ImmunoMetabolism: Molecular and Cellular Immunology of Metabolism.
27. Beretta L. New markers for screening and diagnosis. 1st Annual Conference of the International Liver Cancer Association.
28. Beretta L. Pathogenesis of hepatocellular carcinoma from chronic HCV infection. Symposium on Epidemiology and Pathophysiology of Infection-associated Cancers, Vaccine and Infectious Disease Institute.
29. Beretta L. Proteomics applied to the study of hepatitis C virus-associated liver cancer. 6th Annual International Cancer Conference.
30. Beretta L. Proteome Profiling. GOT Summit - Getting Optimized Tools for Diagnostics, Cambridge Healthtech Institute.
31. Beretta L. 4th International Conference on Genomics, Proteomics, Bioinformatics and Nanobiotechnology for Medicine (GPBNM 2008).
32. Beretta L. Alcoholic Liver Disease Cirrhosis. Basque Government and Diputacion Foral de Bizkaia, CIBERehd and CICbioGUN.
33. Beretta L. Strategies for biomarker discovery as applied to liver cancer. 7th Annual World Congress of the Human Proteome Organization.
34. Beretta L. Biomarkers for the early detection of HCC: summary of a discovery phase. 13th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD).
35. Beretta L. The extracellular matrix (ECM) dynamics in live disease progression to hepatocellular carcinoma (HCC): a proteomics study. The Liver Meeting 2010: American Association for the Study of Liver Diseases (AASLD) 61st Annual Meeting.
36. Beretta L. HCC: testing and discovery of biomarkers. The Liver Meeting 2010: American Association for the Study of Liver Diseases (AASLD) 61st Annual Meeting.
37. Beretta L. Host cell proteome changes upon HCV infection. The Liver Meeting 2010: American Association for the Study of Liver Diseases (AASLD) 61st Annual Meeting.
38. Beretta L. Comparative Proteomic Studies in Hepatocellular Carcinoma. EMBO Conference Series on Cancer Proteomics: Systems Biology, Developmental Models, and Data Integration.
39. Beretta L. Liver Cancer Biomarker. Liver Cancer Biomarker Workshop.
40. Beretta L. 14th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD).
41. Beretta L. Cancers I: Integrated Approaches to Proteomics. HUPO 2012, 11th Annual World Congress.
42. Beretta L. The Liver Meeting 2012: American Association for the Study of Liver Diseases (AASLD) 63rd Annual Meeting.
43. Beretta L. Proteomics, Mass Spectrometry and Petidomics. V Symposium of Mexican Proteomics Society.
44. Beretta L. Human Liver B/D Initiative. HUPO 2014: 13th World Congress of the Human Proteome.
45. Beretta L. Health Minority Conference. 7th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved.
46. Beretta L. HCC Conference. Hepatobiliary Cancers: Pathobiology and Translations Advances.
47. Beretta L. Inflammation in Cancer. Inflammation in Cancer.
48. Beretta L. Biomarkers for the early detection of HCC. Biomarkers for the early detection of HCC.
49. Tang S, Kwan SY, Jiao J, McDaniel A, Beretta L. TAK-242 and Rifaximin as a Novel Treatment for Hepatocellular Carcinoma. 2019 CPRIT Research Training Program at MD Anderson Cancer Center.
50. Beretta L. Human Liver Proteome Project (HLPP) and liver biomarkers for disease. 3rd International Barbados Proteomics Conference.
51. Beretta L. Genomics and proteomics for biomarker discovery. Sixth International Liver Congress.
52. Beretta L. Proteomic technologies for HCC biomarker discovery. Hepatitis B Foundation Princeton Workshop.
53. Shang S, Wang H, Hanash S, Beretta L. Biomarker Discovery for Early Diagnosis of Hepatocellular Carcinoma. 5th HUPO World Congress.
54. Mannova P, Fang R, Wang H, Deng B, McIntosh MW, Hanash SM, Beretta L. Modification of Host Lipid Raft Proteome upon Hepatitis C Virus Replication. 5th HUPO World Congress.
55. Lin S-B, Kolippakkam D, Lai M-Y, Chen D-S, Beretta L. Glycopeptide Profiling as a Tool to Discover Novel Markers of Disease Progression in Liver Fibrosis. 5th HUPO World Congress.
56. Beretta L. Integrative analysis of the liver proteome as a strategy for liver disease biomarker discovery. 5th HUPO World Congress.
57. Wang H, Parent R, Kolippakkam D, Hanash S, Beretta L. Label-free Mass Spectrometry-based Differential Proteome of Secreted Proteins Following Interferon-Treatment of Differentiated Liver Progenitor Cells. 5th HUPO World Congress.
58. Kolippakkam D, Shang S, Feng J, Beretta L. Comprehensive Analysis of the Human Liver Proteome Project (HLPP) Reference Liver Specimen. 5th HUPO World Congress.
59. Beretta L. Integrative analysis of the liver proteome as a strategy for liver disease biomarker discovery. 2006 Joint 3rd AOHUPO and 4th Structural Biology and Functional Genomics Conference.
60. Beretta L. Integrative analysis of the liver proteome as a strategy for liver disease biomarker discovery. USHUPO Third Annual Conference (United States Human Proteome Organization).
61. Beretta L. Human Liver Proteome Project (HLPP). 1st Annual Iberoamerican Proteomics Congress.
62. Beretta L. Integrative analysis of the liver proteome as a strategy for liver disease biomarker discovery. 1st Annual Iberoamerican Proteomics Congress.
63. Beretta L. Integrative analysis of the liver proteome as a strategy for liver disease biomarker discovery. International Agency for Research on Cancer (Translational Worldwide Perspective for Liver Cancer).

Book Chapters

1. Beretta L. The Liver Proteome. In: The Liver: Biology and Pathobiology. 5th. Wiley-Blackwell, 961-963, 2009.

Patents

1. Beretta L. Liver Cancer Biomarkers, 2007. Patent Number: 8067152.
2. Beretta L, Baron S. Method of Regulating SMN Gene Expression, 2000. Patent Number: WO2000021553A3.
3. Hanash SM, Beretta L, LeNaour F. Detection and Treatment of Cancers of the Liver. Patent Number: 7387881.
4. Beretta L. Upregulation of Interferon gene expression. Patent Number: ***.